SELLAS Life Sciences (SLS) Announces Proposed Underwritten Public Offering

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. All of the securities in the offering will be sold by SELLAS.

SVB Leerink and Cantor are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

You May Also Be Interested In

• Global Water Resources raises $20M through stock sale and credit line
• SailPoint Technologies Holdings (SAIL) PT Raised to $25 by Cantor Fitzgerald on Solid Checks
• BiomX to rename itself Tessera Defense, ticker changes to HLSQ